Stability Studies vs. Protein Therapeutics

An interview with Christopher Bravery, Director of Consulting, Advanced Biologicals Ltd.

We recently sat down with Christopher Bravery, Director of Consulting at Advanced Biologicals Ltd. to discuss stability issues and how they differ between cell therapy development and antibody development, analytical methods for cell therapy development, and what is still needed in terms of stability.

There is a myriad of issues around cell therapy and you have two basic choices to make in early development; will I provide this as a fresh product or a¬†cryopreserved product. There are pros and cons to both, so what does the future hold in terms of development in order to make a huge difference in commercialization? ¬† Watch the interview below to hear what Christopher has to say on these topics and many more…

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s